AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 73; no. 3; pp. 531 - 534
Main Authors Ivashchenko, Andrey A, Dmitriev, Kirill A, Vostokova, Natalia V, Azarova, Valeria N, Blinow, Andrew A, Egorova, Alina N, Gordeev, Ivan G, Ilin, Alexey P, Karapetian, Ruben N, Kravchenko, Dmitry V, Lomakin, Nikita V, Merkulova, Elena A, Papazova, Natalia A, Pavlikova, Elena P, Savchuk, Nikolay P, Simakina, Elena N, Sitdekov, Tagir A, Smolyarchuk, Elena A, Tikhomolova, Elena G, Yakubova, Elena V, Ivachtchenko, Alexandre V
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 02.08.2021
Subjects
Antiviral Agents - therapeutic use
Brief Reports
COVID-19
Drug Therapy, Combination
Humans
SARS-CoV-2
Treatment Outcome
COVID-19
SARS-CoV-2
favipiravir
AVIFAVIR
Online AccessGet full text

Cover

More Information
Summary:In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciaa1176